DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Chris Schott - 1 Eliav Barr - 1 PAH - 1 Barr - 1 Merck - 1
Top related locs:
Rahway , New Jersey U.S Winrevair
Top related orgs:
Merck - 1 Drug Administration - 1 JPMorgan - 1 CNBC - 1 Acceleron Pharma - 1

Search resuls for: "Acceleron Pharma"


5 mentions found


☆ FDA approves Merck's drug for rare, deadly lung condition
  + stars: | 2024-03-26 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The condition refers to when the small blood vessels in the lungs narrow. He noted that the drug will be a "paradigm shift" for patients living with PAH. That includes reducing the risk of death or worsening of the condition by 84% compared to an existing drug alone. Those trials include late-stage studies on patients with more advanced PAH disease, and those who are within the first year after diagnosis.
Persons: Chris Schott, Eliav Barr, PAH, Barr, Merck Organizations: Merck, Drug Administration, JPMorgan, CNBC, Acceleron Pharma Locations: Rahway , New Jersey, U.S, Winrevair
☆ Farallon steps up activism at biotech company Exelixis. Here’s what could happen next
  + stars: | 2023-04-15 | by ( Kenneth Squire | ) www.cnbc.com   time to read: +9 min
Farallon is not an activist investor but will pursue an activist agenda when it feels forced to do so. As the strategy of shareholder activism has become more mainstream, it has been utilized by a larger breadth of investors. The firm has been a shareholder of Exelixis since 2018 and is just now going public with their concerns. Farallon would also like to see Exelixis commit to a much larger share repurchase program than the $550 million it has announced. Farallon is nominating only three directors to this board, and it befuddles us as to how Exelixis does not see this as a gift.
☆ Merck's drug boosts exercise capacity in pulmonary hypertension patients
  + stars: | 2023-03-06 | by ( Khushi Mandowara | ) www.reuters.com   time to read: +2 min
Sotatercept, combined with a background therapy, helped patients with pulmonary arterial hypertension to walk about 40.8 meters more in six minutes. J.P. Morgan analyst Chris Schott said the data exceeded the brokerage's expectations and "should confirm the drug as go-to add-on therapy" for pulmonary arterial hypertension. Schott forecast peak sales of $3 billion to $4 billion for the drug. In October, Merck said sotatercept had met the main goal of a late-stage study, but did not release the full data. Reporting by Khushi Mandowara and Pratik Jain in Bengaluru; Editing by Arun Koyyur and Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.
☆ Merck to acquire Imago BioSciences for $1.35 bln
  + stars: | 2022-11-21 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +1 min
Nov 21 (Reuters) - Merck & Co Inc (MRK.N) said on Monday it will acquire cancer drug developer Imago BioSciences Inc (IMGO.O) for a total equity value of $1.35 billion to expand its portfolio of blood disorder treatments. The drugmaker's offer of $36 per share in cash for Imago represents a nearly 107% premium to the company's last close. With Merck's blockbuster cancer immunotherapy Keytruda expected to lose key patents in 2028, the company has been trying to expand its drug portfolio. Imago, which develops drugs for the treatment of bone marrow-related diseases, is currently testing its lead drug bomedemstat for treating a chronic cancer known as myeloproliferative neoplasms. The Imago deal is expected to close in the first quarter of 2023, according to the companies.
☆ Merck's blood vessel disorder drug succeeds in late-stage study
  + stars: | 2022-10-10 | by ( ) www.reuters.com   time to read: +1 min
Oct 10 (Reuters) - Merck & Co (MRK.N) said on Monday a therapy it gained through the drugmaker's $11.5 billion acquisition of Acceleron Pharma last year met the main goal of a late-stage study in patients with a progressive blood vessel disorder. Sotatercept, when compared to placebo, significantly extended how far patients with pulmonary arterial hypertension (PAH) could walk in six minutes. The trial data validates the Acceleron acquisition, and also supports Merck's budding portfolio of cardiovascular drugs, Truist Securities analyst Robyn Karnauskas said in a note. Pulmonary arterial hypertension is a rare type of high blood pressure that affects an estimated 40,000 people in the United States, according to Merck. Register now for FREE unlimited access to Reuters.com RegisterReporting by Khushi Mandowara and Mrinalika Roy in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 5